• All Categories
  • Infectious Diseases
  • Rare Diseases
  • Dermatology
  • Oncology
  • Respiratory
  • Pain
  • Neurology
  • Cardiovascular
  • Women's Health
  • News
Pharmafile 2024
Pharmafile 2024

Therapeutic areas in focus

5 January 2024
Introducing our new digital edition website
Introducing our new digital edition website

Pharmafile is excited to announce the launch of our brand new website, where you can find everything Pharmafile!

5 January 2024
Partnerships and collaborations within the pharmaceutical industry
Partnerships and collaborations within the pharmaceutical industry

In any industry, companies must innovate and collaborate in order to drive their growth and success, and in the life sciences industry this is now more important than ever.

5 January 2024
Readership Breakdown
Readership Breakdown

Pharmafile is distributed to over 20,000 life science professionals and sponsors a number of international trade events throughout the year, enabling advertisers to reach a wide audience.

5 January 2024
Digital Opportunities
Digital Opportunities

Take advantage of Samedan’s e-marketing service to send targeted emails to more than 50,000 digital subscribers.

5 January 2024
Pharmafocus Pharmafile
Pharmafocus Pharmafile

Pharmafile.com

5 January 2024
Contents
Contents

This issue includes the latest news, as well as articles on Cardiovascular and Metabolic Diseases, Women's Health, and Oncology.

1 October 2023
INTCR
INTCR

Www.pharmatimes.com/intcr

1 October 2023
Comment
Comment

Welcome to the autumn 2023 issue of Pharmafile! As the summer draws to a close, it is an ideal time to consider 2023 so far and where it might take us in the remaining months.

1 October 2023
Pharmafile autumn 2023
Pharmafile autumn 2023

Welcome to the Autumn 2023 issue of Pharmafile!

1 October 2023
Pharmafile
Pharmafile

Www.pharmafile.com

1 October 2023
Pfizer’s RSV vaccine recommended by CDC
Pfizer’s RSV vaccine recommended by CDC

Pfizer has announced that the CDC Advisory Committee on Immunization Practices (ACIP) has recommended the company’s bivalent respiratory syncytial virus (RSV) vaccine, Abrysvo, for maternal immunisation.

1 October 2023News